Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.57 |
| ▸ | PARG | Q86W56 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517583 | 0.86 | PARG (0.58) | GABRA1GABRA5GRIN1GRIN2BPARG | |
| SCHEMBL24406022 | 0.83 | ALDH1A1 (0.59) | GRIN1GRIN2BPARGALDH1A1 | |
| SCHEMBL14992630 | 0.78 | GRIN1 (0.52) | GRIN1GRIN2BPARG | |
| SCHEMBL25827046 | 0.76 | CYP3A4 (0.55) | GABRA5GRIN1GRIN2BPARG | |
| SCHEMBL16695676 | 0.75 | GBA1 (0.54) | ALDH1A1 | |
| SCHEMBL2497505 | 0.74 | LMNA (0.71) | GABRA1GABRA5ALDH1A1 | |
| SCHEMBL31122012 | 0.74 | PARG (1.00) | PARG | |
| SCHEMBL30345117 | 0.73 | LMNA (0.62) | GABRA1GABRA5GRIN1GRIN2BALDH1A1 | |
| SCHEMBL4915023 | 0.73 | LMNA (0.62) | GABRA1GABRA5GRIN1GRIN2BALDH1A1 | |
| SCHEMBL29888839 | 0.73 | GRIN1 (1.00) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| EP-0005610-B1 | 1-(HETEROCYCLYLALKYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONES, THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS BETA-ADRENERGIC RECEPTOR BLOCKERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-12-15 | — | — | EP | disclosed |
| US-4181802-A | ADRENERGIC BLOCKING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-01-01 | — | — | US | disclosed |
| EP-0005610-A2 | 1-(Heterocyclylalkyl)-1,3-dihydro-2H-benzimidazol-2-ones, their preparation, their pharmaceutical compositions and their use as beta-adrenergic receptor blockers | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | GABRA1 1454/4885GABRA5 2077/4885GRIN1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.